Abstracts Archive - Page 275 of 2607 - ACR Meeting Abstracts

Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Eric Morand¹, Cristina Arriens², Laura Geraldino³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁶, Ravi Koti⁵, Subhashis Banerjee⁵ and Ronald Van Vollenhoven⁷, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
Abstract Number: 0665 • ACR Convergence 2024
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
Nicolai Leuchten¹, Ioannis Parodis², Ralph Brinks³ and Martin Aringer¹, ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ³University Witten/Herdecke, Witten, Germany
Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0668 • ACR Convergence 2024
There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY
Kiera Brennan¹, Kai Sun², Anitha Ramu¹, Juliann Allen¹, Justina Shafik¹ and Noa Schwartz³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Duke University, Durham, NC, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is associated with poor outcomes in SLE.1 Electronic Health Record (EHR) platforms collect data on patient medication access through dispensing…
Abstract Number: 0507 • ACR Convergence 2024
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Runa Kuley¹, Bhargavi Duvvuri¹, Sabeeha Hasnain², Ernst Dow³, Alisa Koch⁴, Richard Higgs⁴, Venkatesh Krishnan⁴ and Christian Lood⁵, ¹University of Washington, Seattle, ²Mahindra University, Hyderabad, India, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
Abstract Number: 0661 • ACR Convergence 2024
Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, and AURORA, ¹Rush University Medical Center, Chicago, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Aurinia Pharmaceuticals, Dallas
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 0655 • ACR Convergence 2024
Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
Minjee Park¹, Sofia Pedro², Jean-Francois Ricci¹, Kaleb Michaud³ and Patti Katz⁴, ¹Alira Health, Basel, Switzerland, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Welch¹, Yangyuna Yang¹, Joshua Baker², Katherine Wysham³, Dana Ascherman⁴, Paul Monach⁵, Gail Kerr⁶, Andreas Reimold⁷, grant Cannon⁸, Gary Kunkel⁹, William Robinson¹⁰, Michael Duryee¹, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵VA Boston Healthcare System, Boston, MA, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷Dallas VA Medical Center, Dallas, TX, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰Stanford University, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0628 • ACR Convergence 2024
Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Meghan Nelson¹, Shanta Murthy², Sushma Maddipatla², Sreekala Shenoy², Lori Ponder³, Subra Kugathasan⁴, Dave Cutler⁵ and Sampath Prahalad⁶, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland; Department of Human Genetics; Emory University School of Medicine, Atlanta, Georgia, United States of America, Bethesda, MD, ²Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America, Atlanta, GA, ⁵Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ⁶Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease with significant morbidity and mortality. Genome-wide association studies have identified more than 100 variants…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 0553 • ACR Convergence 2024
Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
Sanjeev Shrestha¹, Angela Bobak², Idorenyin Udoeyo³, Pradeep Puri⁴, Jordan Law⁵ and David Bulbin⁶, ¹Geisinger Medical Center, Bloomsburg, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Danville, ⁵Geisinger Health System, Danville, ⁶Geisinger Health System, Danville, PA
Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
Abstract Number: 0545 • ACR Convergence 2024
Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Stylianos Georgiadis¹, Marion Pons², Simon Horskjær Rasmussen², Merete Hetland³, Louise Linde², Daniela DiGuiseppe⁴, Brigitte Michelsen⁵, Johan Karlsson Wallman⁶, Tor Olofsson⁷, Karel Pavelka⁸, Jakub Závada⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Catalin Codreanu¹¹, Daniel Melim¹², Diogo Esperança Almeida¹³, Tore K. Kvien¹⁴, Vappu Rantalaiho¹⁵, Ritva Peltomaa¹⁶, Bjorn Gudbjornsson¹⁷, Olafur Palsson¹⁸, Ovidiu Rotariu¹⁹, Ross MacDonald¹⁹, Ziga Rotar²⁰, Katja Perdan-Pikmajer²⁰, Karin Laas²¹, Florenzo Iannone²², Adrian Ciurea²³, Mikkel Ostergaard²⁴ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁴Karolinska Institutet, Stockholm, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁸Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹University of Medicine and Pharmacy, Bucharest, Romania, ¹²Hospital Egas Moniz, Lisbon, Portugal, ¹³Hospital de Braga, Braga, Portugal, ¹⁴Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁵Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ¹⁶Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ¹⁷Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁸University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁹University of Aberdeen, Aberdeen, United Kingdom, ²⁰University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ²¹East-Tallinn Central Hospital, Tallinn, Estonia, ²²Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²³University Hospital Zurich, Zürich, Switzerland, ²⁴Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].